Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last CNY5.62 CNY
Change Today +0.04 / 0.72%
Volume 4.2M
As of 3:05 AM 09/30/15 All times are local (Market data is delayed by at least 15 minutes).

tianjin tianyao pharm-a (600488) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/12/15 - CNY13.29
52 Week Low
09/15/15 - CNY5.37
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TIANJIN TIANYAO PHARM-A (600488)

Related News

No related news articles were found.

tianjin tianyao pharm-a (600488) Related Businessweek News

No Related Businessweek News Found

tianjin tianyao pharm-a (600488) Details

Tianjin Tianyao Pharmaceuticals Co., Ltd. engages in the research, manufacture, and sale of pharmaceutical APIs in Asia. It primarily offers corticosteroid, cardio cerebrovascular, and analgesic APIs and formulations. The company’s product portfolio includes bulk drugs, such as dexamethasone, dexamethasone sodium phosphate, dexamethasone acetate, triamcinlone acetonide acetate, prednisone acetate, prednisone, prednisolone, flucinonide, halcinonide, triamcinolone acetonide, clobetasol propionate, betamethasone, spironolactone, methylprednisolone hemisuccinate, hydrocortisone butyrate, hydrocortisone, hydrocortisone acetate, methylprednisolone, triamcinolone, bucinnazine hydrochloride, and flunarizine hydrochloride. It also offers formulations, which include triamcinolone, dexamethasone acetate, prednisone acetate, and methylprednisolone tablets. The company also exports its products. Tianjin Tianyao Pharmaceuticals Co., Ltd. is based in Tianjin, China.

tianjin tianyao pharm-a (600488) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

tianjin tianyao pharm-a (600488) Key Developments

Tianjin Tianyao Pharmaceuticals Co., Ltd. Announces Earnings Results for the First Half Year of 2015

Tianjin Tianyao Pharmaceuticals Co., Ltd. announced earnings results for the first half year of 2015. For the period, the company reported basic earnings per share of CNY 0.049 and weighted average return on net assets of 1.97%.

Tianjin Tianyao Pharmaceuticals Co., Ltd., Board Meeting, Aug 27, 2015

Tianjin Tianyao Pharmaceuticals Co., Ltd., Board Meeting, Aug 27, 2015. Agenda: To discuss and approve the semi-annual report of 2015; and to discuss the proposal of special report on deposit and actual usage of raised funds in the first half of 2015.

Tianjin Tianyao Pharmaceuticals Co., Ltd. to Report First Half, 2015 Results on Aug 28, 2015

Tianjin Tianyao Pharmaceuticals Co., Ltd. announced that they will report first half, 2015 results on Aug 28, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
600488:CH CNY5.62 CNY +0.04

600488 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 600488.
View Industry Companies

Industry Analysis


Industry Average

Valuation 600488 Industry Range
Price/Earnings 53.8x
Price/Sales 3.8x
Price/Book 2.2x
Price/Cash Flow 53.4x
TEV/Sales 3.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TIANJIN TIANYAO PHARM-A, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at